Rhythm Pharmaceuticals, Inc.
RYTM
$93.72
$2.412.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 60.11M | 57.25M | 51.30M | 48.50M | 32.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.11M | 57.25M | 51.30M | 48.50M | 32.70M |
| Cost of Revenue | 7.16M | 4.80M | 5.50M | 5.54M | 3.65M |
| Gross Profit | 52.96M | 52.45M | 45.80M | 42.96M | 29.06M |
| SG&A Expenses | 63.59M | 57.48M | 52.43M | 45.95M | 39.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.47M | 104.32M | 103.95M | 93.80M | 79.71M |
| Operating Income | -52.36M | -47.06M | -52.65M | -45.30M | -47.00M |
| Income Before Tax | -55.09M | -47.54M | -52.79M | -46.30M | -49.42M |
| Income Tax Expenses | 545.00K | -31.00K | 111.00K | 337.00K | 80.00K |
| Earnings from Continuing Operations | -55.64M | -47.51M | -52.90M | -46.63M | -49.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.64M | -47.51M | -52.90M | -46.63M | -49.50M |
| EBIT | -52.36M | -47.06M | -52.65M | -45.30M | -47.00M |
| EBITDA | -52.11M | -46.79M | -52.35M | -44.92M | -46.62M |
| EPS Basic | -0.83 | -0.73 | -0.82 | -0.75 | -0.81 |
| Normalized Basic EPS | -0.51 | -0.44 | -0.50 | -0.45 | -0.49 |
| EPS Diluted | -0.83 | -0.73 | -0.82 | -0.75 | -0.81 |
| Normalized Diluted EPS | -0.51 | -0.44 | -0.50 | -0.45 | -0.49 |
| Average Basic Shares Outstanding | 67.97M | 66.88M | 66.26M | 63.68M | 63.06M |
| Average Diluted Shares Outstanding | 67.97M | 66.88M | 66.26M | 63.68M | 63.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |